Access the full text.
Sign up today, get DeepDyve free for 14 days.
(1998)
WONG S, MULLER J et al
L. Noel (2012)
Global regulatory requirements for xenotransplantation clinical trials *Xenotransplantation, 19
D. Kaulitz, Debora Mihica, J. Dorna, Michael Costa, B. Petersen, H. Niemann, R. Tönjes, J. Denner (2011)
Development of sensitive methods for detection of porcine endogenous retrovirus-C (PERV-C) in the genome of pigs.Journal of virological methods, 175 1
Weihong Xu, Junhee Seok, M. Mindrinos, A. Schweitzer, Hui Jiang, J. Wilhelmy, Tyson Clark, K. Kapur, Yi Xing, M. Faham, John Storey, L. Moldawer, R. Maier, R. Tompkins, W. Wong, Ronald Davis, Wenzhong Xiao (2011)
Human transcriptome array for high-throughput clinical studiesProceedings of the National Academy of Sciences, 108
S. Wynyard, D. Nathu, O. Garkavenko, J. Denner, R. Elliott (2014)
Microbiological safety of the first clinical pig islet xenotransplantation trial in New ZealandXenotransplantation, 21
B. Lin, A. Malanoski, Zheng Wang, K. Blaney, Nina Long, C. Meador, D. Metzgar, Christopher Myers, S. Yingst, M. Monteville, M. Saad, J. Schnur, C. Tibbetts, D. Stenger (2009)
Universal Detection and Identification of Avian Influenza Virus by Use of Resequencing MicroarraysJournal of Clinical Microbiology, 47
M. Kimsa, B. Strzałka-Mrozik, M. Kimsa, J. Gola, P. Nicholson, K. Lopata, U. Mazurek (2014)
Porcine Endogenous Retroviruses in Xenotransplantation—Molecular AspectsViruses, 6
(2001)
Draft Guideline on the Risk-based Approach According to Annex I, part IV of Directive
J. Tenenbaum, Susanna-Assunta Sansone, M. Haendel (2013)
A sea of standards for omics data: sink or swim?Journal of the American Medical Informatics Association : JAMIA, 21
(2008)
F, BOEKE JD
A. Gunawan, Sudeep Sahadevan, M. Çınar, C. Neuhoff, C. Große-Brinkhaus, L. Frieden, D. Tesfaye, E. Tholen, C. Looft, D. Wondim, M. Hölker, K. Schellander, M. Uddin (2013)
Identification of the Novel Candidate Genes and Variants in Boar Liver Tissues with Divergent Skatole Levels Using RNA Deep SequencingPLoS ONE, 8
J. Ramsoondar, T. Vaught, S. Ball, M. Mendicino, Jeff Monahan, P. Jobst, A. Vance, J. Duncan, K. Wells, D. Ayares (2009)
Production of transgenic pigs that express porcine endogenous retrovirus small interfering RNAsXenotransplantation, 16
(2002)
of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research (CBER)
Annalisa Ballarini, N. Segata, C. Huttenhower, O. Jousson (2013)
Simultaneous Quantification of Multiple Bacteria by the BactoChip Microarray Designed to Target Species-Specific Marker GenesPLoS ONE, 8
M. Irgang, A. Karlas, C. Laue, V. Specke, S. Tacke, R. Kurth, J. Schrezenmeir, J. Denner (2005)
Porcine Endogenous Retroviruses PERV-A and PERV-B Infect neither Mouse Cells in vitro nor SCID Mice in vivoIntervirology, 48
Marwan Semaan, A. Rotem, U. Barkai, S. Bornstein, J. Denner (2013)
Screening pigs for xenotransplantation: prevalence and expression of porcine endogenous retroviruses in Göttingen minipigsXenotransplantation, 20
(2000)
WONG S, VANBROCKLIN M, FEDERSPIEL MJ
C. Patience, Y. Takeuchi, R. Weiss (1997)
Infection of human cells by an endogenous retrovirus of pigsNature Medicine, 3
(2013)
Update on assays for detection of PERVsXenotransplantation, 20
A. Gunawan, Sudeep Sahadevan, C. Neuhoff, C. Große-Brinkhaus, A. Gad, L. Frieden, D. Tesfaye, E. Tholen, C. Looft, M. Uddin, K. Schellander, M. Çınar (2013)
RNA Deep Sequencing Reveals Novel Candidate Genes and Polymorphisms in Boar Testis and Liver Tissues with Divergent Androstenone LevelsPLoS ONE, 8
R. Stoughton (2005)
Applications of DNA microarrays in biology.Annual review of biochemistry, 74
W. Zou, Dijun Chen, Min Xiong, Jiping Zhu, Xian Lin, Lun Wang, Jun Zhang, Lingling Chen, Hongyu Zhang, Huanchun Chen, Ming Chen, M. Jin (2013)
Insights into the increasing virulence of the swine-origin pandemic H1N1/2009 influenza virusScientific Reports, 3
M. Groenen, A. Archibald, H. Uenishi, C. Tuggle, Y. Takeuchi, M. Rothschild, C. Rogel-Gaillard, Chankyu Park, D. Milan, H. Megens, Shengting Li, D. Larkin, Heebal Kim, Laurent Frantz, M. Cáccamo, Hyeonju Ahn, Bronwen Aken, A. Anselmo, Christian Anthon, L. Auvil, B. Badaoui, C. Beattie, C. Bendixen, Daniel Berman, F. Blecha, J. Blomberg, L. Bolund, M. Bosse, S. Botti, Zhan Bujie, Megan Bystrom, Boris Capitanu, D. Carvalho-Silva, P. Chardon, Celine Chen, R. Cheng, Sang-Haeng Choi, W. Chow, R. Clark, C. Clee, R. Crooijmans, H. Dawson, P. Déhais, Fioravante Sapio, B. Dibbits, N. Drou, Z. Du, K. Eversole, J. Fadista, S. Fairley, T. Faraut, G. Faulkner, K. Fowler, M. Fredholm, E. Fritz, J. Gilbert, E. Giuffra, J. Gorodkin, D. Griffin, J. Harrow, Alexander Hayward, K. Howe, Zhi-Liang Hu, S. Humphray, T. Hunt, H. Hornshøj, J. Jeon, P. Jern, Matthew Jones, J. Jurka, H. Kanamori, R. Kapetanovic, Jaebum Kim, Jae-hwan Kim, Kyu-Won Kim, Tae-Hun Kim, G. Larson, Kyooyeol Lee, Kyung-Tai Lee, R. Leggett, H. Lewin, Yingrui Li, Wansheng Liu, J. Loveland, Yao Lu, J. Lunney, Jian Ma, O. Madsen, Katherine Mann, L. Matthews, Stuart Mclaren, T. Morozumi, M. Murtaugh, Jitendra Narayan, Dinh Nguyen, Peixiang Ni, S. Oh, S. Onteru, F. Panitz, E. Park, Hong-Seog Park, G. Pascal, Yogesh Paudel, M. Pérez-Enciso, R. Ramírez-González, J. Reecy, S. Rodriguez-Zas, G. Rohrer, L. Rund, Y. Sang, K. Schachtschneider, J. Schraiber, J. Schwartz, L. Scobie, C. Scott, S. Searle, B. Servin, B. Southey, G. Sperber, P. Stadler, J. Sweedler, Hakim Tafer, B. Thomsen, R. Wali, Jian Wang, Jun Wang, S. White, Xun Xu, M. Yerle, Guojie Zhang, Jianguo Zhang, Jie Zhang, Shuhong Zhao, J. Rogers, C. Churcher, L. Schook (2012)
Analyses of pig genomes provide insight into porcine demography and evolutionNature, 491
Guidance for Industry: Source Animal, Product, Preclinical, and Clinical Issues Concerning the Use of Xenotransplantation Products in Humans
(2008)
COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)
Z. Ivics, W. Garrels, L. Mátés, T. Yau, S. Bashir, V. Zídek, V. Landa, A. Geurts, M. Pravenec, T. Rülicke, W. Kues, Z. Izsvák (2014)
Germline transgenesis in pigs by cytoplasmic microinjection of Sleeping Beauty transposonsNature Protocols, 9
(2014)
EKSER B, MENKIS AH, COOPER DK
Carolyn Wilson, Susan Wong, M. VanBrocklin, M. Federspiel (2000)
Extended Analysis of the In Vitro Tropism of Porcine Endogenous RetrovirusJournal of Virology, 74
David Wang, L. Coscoy, M. Zylberberg, P. Avila, H. Boushey, D. Ganem, J. Derisi (2002)
Microarray-based detection and genotyping of viral pathogensProceedings of the National Academy of Sciences of the United States of America, 99
S. Wynyard, O. Garkavenko, R. Elliot (2011)
Multiplex high resolution melting assay for estimation of Porcine Endogenous Retrovirus (PERV) relative gene dosage in pigs and detection of PERV infection in xenograft recipients.Journal of virological methods, 175 1
H. Hackl, T. Burkard, A. Sturn, Renee Rubio, A. Schleiffer, Sun Tian, John Quackenbush, F. Eisenhaber, Z. Trajanoski (2005)
Molecular processes during fat cell development revealed by gene expression profiling and functional annotationGenome Biology, 6
A. Karlas, R. Kurth, J. Denner (2004)
Inhibition of porcine endogenous retroviruses by RNA interference: increasing the safety of xenotransplantation.Virology, 325 1
W. Seifarth, B. Spiess, Udo Zeilfelder, C. Speth, R. Hehlmann, C. Leib-Mösch (2003)
Assessment of retroviral activity using a universal retrovirus chip.Journal of virological methods, 112 1-2
Britta Dieckhoff, B. Petersen, W. Kues, R. Kurth, H. Niemann, J. Denner (2008)
Knockdown of porcine endogenous retrovirus (PERV) expression by PERV‐specific shRNA in transgenic pigsXenotransplantation, 15
Britta Dieckhoff, A. Karlas, A. Hofmann, W. Kues, B. Petersen, Alexander Pfeifer, H. Niemann, R. Kurth, J. Denner (2006)
Inhibition of porcine endogenous retroviruses (PERVs) in primary porcine cells by RNA interference using lentiviral vectorsArchives of Virology, 152
(2004)
Regulation (EC) No 1394/2007 of the European Parliament and of the Council of 13
Carolyn Wilson, Susan Wong, J. Muller, C. Davidson, T. Rose, P. Burd (1998)
Type C Retrovirus Released from Porcine Primary Peripheral Blood Mononuclear Cells Infects Human CellsJournal of Virology, 72
(2001)
Supplemental guidance on testing for replication-competent retrovirus in retroviral vector-based gene therapy products and during follow-up of patients in clinical trials using retroviral vectors.
Huidong Zhou, H. Iwase, R. Wolf, B. Ekser, M. Ezzelarab, H. Hara, G. White, D. Cooper (2014)
Are there advantages in the use of specific pathogen‐free baboons in pig organ xenotransplantation models?Xenotransplantation, 21
(2014)
HAENDEL M
Han-Chung Hsiue, Y. Huang, Y.-l. Kuo, C. Liao, T. Chang, P. Hsueh (2010)
Rapid identification of fungal pathogens in positive blood cultures using oligonucleotide array hybridization.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 16 5
Pawel Labaj, G. Leparc, B. Linggi, L. Markillie, H. Wiley, David Kreil (2011)
Characterization and improvement of RNA-Seq precision in quantitative transcript expression profilingBioinformatics, 27
Maqc Consortium (2006)
The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurementsNature Biotechnology, 24
Wilson (1998)
Type C retrovirus released from porcine primary peripheral blood mononuclear cells infects human cellsJ Virol, 72
B. Arezi, Nilanjan Guha, A. Lucas (2012)
Gene Expression Profi ling and Validation Using Agilent SurePrint G3 Gene Expression Arrays
(2013)
Safe transplantation. Lifeline. Medical research for healthy livesInt Innov, 1
Michael Costa, N. Fischer, Barbara Gulich, R. Tönjes (2014)
Comparison of porcine endogenous retroviruses infectious potential in supernatants of producer cells and in coculturesXenotransplantation, 21
Gordon Robertson, J. Schein, Readman Chiu, R. Corbett, M. Field, S. Jackman, K. Mungall, Sam Lee, H. Okada, Jenny Qian, M. Griffith, Anthony Raymond, N. Thiessen, T. Cezard, Y. Butterfield, R. Newsome, S. Chan, R. She, R. Varhol, Baljit Kamoh, A. Prabhu, Angela Tam, Yongjun Zhao, Richard Moore, M. Hirst, M. Marra, Steven Jones, P. Hoodless, I. Birol (2010)
De novo assembly and analysis of RNA-seq dataNature Methods, 7
R. Manji, B. Ekser, A. Menkis, D. Cooper (2014)
Bioprosthetic heart valves of the futureXenotransplantation, 21
O. Garkavenko, S. Wynyard, D. Nathu, M. Muzina, Z. Muzina, L. Scobie, R. Hector, Margaret Croxson, P. Tan, B. Elliott (2008)
Porcine endogenous retrovirus transmission characteristics from a designated pathogen-free herd.Transplantation proceedings, 40 2
(2001)
MAO M, JONES AR et al
(2003)
TAKEUCHI Y, TEMPLIN C et al
(2012)
SCOBIE L, TAKEUCHI Y
Guideline on Human Cell-Based Medicinal Products
T. Ericsson, Y. Takeuchi, C. Templin, G. Quinn, S. Farhadian, James Wood, B. Oldmixon, K. Suling, J. Ishii, Y. Kitagawa, T. Miyazawa, D. Salomon, R. Weiss, C. Patience (2003)
Identification of receptors for pig endogenous retrovirusProceedings of the National Academy of Sciences of the United States of America, 100
Melissa Miller, Yi-Wei Tang (2009)
Basic Concepts of Microarrays and Potential Applications in Clinical MicrobiologyClinical Microbiology Reviews, 22
Zhong Wang, M. Gerstein, M. Snyder (2009)
RNA-Seq: a revolutionary tool for transcriptomicsNature Reviews Genetics, 10
S. Wheelan, F. Murillo, J. Boeke (2008)
The incredible shrinking world of DNA microarrays.Molecular bioSystems, 4 7
J. Denner, R. Tönjes (2012)
Infection Barriers to Successful Xenotransplantation Focusing on Porcine Endogenous RetrovirusesClinical Microbiology Reviews, 25
(2010)
KUO YL et al
(2009)
First WHO Global Consultation on Regulatory Requirements for Xenotransplantation Clinical Trials: Changsha, China, 19-21 November 2008Xenotransplantation, 16
(2014)
STRZALKA-MROZIK B, KIMSA MW et al
A. Waechter, J. Denner (2014)
Novel neutralising antibodies targeting the N-terminal helical region of the transmembrane envelope protein p15E of the porcine endogenous retrovirus (PERV)Immunologic Research, 58
(2011)
LINGGI BE et al
J. Fishman, L. Scobie, Y. Takeuchi (2012)
Xenotransplantation‐associated infectious risk: a WHO consultationXenotransplantation, 19
T. Hughes, M. Mao, Allan Jones, J. Burchard, M. Marton, K. Shannon, S. Lefkowitz, M. Ziman, Janell Schelter, Michael Meyer, Sumire Kobayashi, Colleen Davis, H. Dai, Yudong He, Sergey Stephaniants, G. Cavet, W. Walker, A. West, E. Coffey, D. Shoemaker, R. Stoughton, A. Blanchard, S. Friend, P. Linsley (2001)
Expression profiling using microarrays fabricated by an ink-jet oligonucleotide synthesizerNature Biotechnology, 19
B. Lin, K. Blaney, A. Malanoski, A. Ligler, J. Schnur, D. Metzgar, K. Russell, D. Stenger (2006)
Using a Resequencing Microarray as a Multiple Respiratory Pathogen Detection AssayJournal of Clinical Microbiology, 45
Jia-xu Chen, Mu-xin Chen, L. Ai, Jun-Hu Chen, Shao-Hong Chen, Yong-nian Zhang, Y. Cai, Xing-Quan Zhu, Xiaonong Zhou (2012)
A Protein Microarray for the Rapid Screening of Patients Suspected of Infection with Various Food-Borne HelminthiasesPLoS Neglected Tropical Diseases, 6
E. Leproust (2008)
Agilent ’ s Microarray Platform : How High-Fidelity DNA Synthesis Maximizes the Dynamic Range of Gene Expression Measurements
T. Hai, Fei Teng, Runfa Guo, Wei Li, Qi Zhou (2014)
One-step generation of knockout pigs by zygote injection of CRISPR/Cas systemCell Research, 24
David Wang, A. Urisman, Yu-Tseung Liu, Michael Springer, T. Ksiazek, D Erdman, E. Mardis, M. Hickenbotham, V. Magrini, James Eldred, J. Latreille, Richard Wilson, D. Ganem, Joseph DeRisi (2003)
Viral Discovery and Sequence Recovery Using DNA MicroarraysPLoS Biology, 1
E. Cozzi, M. Tallacchini, E. Flanagan, Richard III, M. Sykes, H. Vanderpool (2009)
Chapter 1: Key ethical requirements and progress toward the definition of an international regulatory frameworkXenotransplantation, 16
(2013)
T€ ONJES RR
Abbreviations ATMP Advanced therapy medicinal product CHMP Committee for Medicinal Products for Human Use EMA European Medicines Agency FDA Food and Drug Administration GMP Good Manufacturing Practice huPBMC human peripheral blood mononuclear cells NGS Next‐generation sequencing PERV Porcine endogenous retrovirus Ph. Eur. European Pharmacopoeia poPBMC porcine peripheral blood mononuclear cells PCR Polymerase chain reaction RT‐PCR Reverse‐transcriptase polymerase chain reaction SPF specific pathogen‐free WHO World Health Organization XTx Xenotransplantation. Introduction For xenotransplantation, pigs show numerous advantages as donor animals compared with other choices such as non‐human primates, which have been established vice versa as recipient animals for preclinical pig organ xenotransplantation . In addition to the anatomical, immunological, and physiological barriers, the risk of infection for the recipient needs to be clarified. Valid and broad‐range detection assays for donor and manufacture derived microorganisms are the method of choice and must be established. These could include microarrays that have already proven their suitability for the screening of retroviruses and/or next‐generation sequencing (NGS)‐based methods . Besides the general microbial detection, the selection of appropriate donor pigs reveals a crucial step. For endogenous retroviruses, this includes the screening for the absence of PERV‐C proviruses in the pig genome, as genetic recombinants between PERV‐A and PERV‐C show high replication titers . Recombination events of this quality should be generally avoided. The pigs should demonstrate low or even no expression of PERV‐A, PERV‐B as well as PERV‐C as the impact of PERV‐A/C recombinants on the health of xenotransplant recipients cannot be fully estimated. They might be exposed to a lifelong challenge with the virus. If putative PERV‐C‐positive animals are considered as donors for transplantation as performed , the quality of PERV‐C sequences, if present in donor animals, should be evaluated for gag , pol ( prt , int , RT), env open reading frames, and LTR structures. Functional PERV‐C needs to be distinguished from non‐functional provirus. Several approaches are established for quality control and characterization of PERVs infective potential. To differentiate between pigs with low and high expression of PERV, assays were developed that are based on mitogen stimulation of PBMCs . Other currently used and well‐known methods to detect and analyze the presence of PERV focus on direct detection of (i) provirus in the cells, (ii) the expression analysis of viral mRNA, (iii) the detection of viral proteins or (iv) the production of infectious viruses itself. The nucleic acid methodology that has been considered as valid testing method also for clinical trials is based on PCR and real‐time PCR methods. Southern blot hybridization using PERV‐specific primers and probes, melting assays to quantify PERV copy numbers, as well as fluorescence in situ hybridization (FISH) for chromosomal localization are additional alternatives. The measurement of viral reverse transcriptase activity (RT test) indicates virus production. Indirect detection of PERV is carried out by analyzing the recipient's antibody immune response. This is mainly based on ELISA, Western blot analysis testing the recipient's sera with purified virus, recombinant protein, or synthetic peptides . Vaccination of human recipients as a strategy to prevent PERV transmission represents a theoretical choice. An approach by induction of neutralizing antibodies has been suggested . A successful inhibition of PERV expression in vitro was achieved by small interfering RNAs (siRNAs) specific for the PERV pol gene . A lentiviral vector expressing a short hairpin RNA (shRNA) of PERV pol led to downregulation of PERV expression in vitro . Similarly, pigs transgenic for the PERV‐specific shRNA showed significantly inhibited PERV expression in different tissues . Analogous results were obtained using siRNAs in vivo . The targeted knockout of PERV, for example, by the application of zinc‐finger nucleases for the generation of genetically modified animals is complicated due to the large number of proviruses The absence of functional PERV‐C as well as the selection of low‐producer animals (PERV‐A/‐B) should be a demand absolute requirement for the generation of donor pigs intended for xenotransplantation. Approaches to achieve PERV knockouts using zinc‐finger nucleases have failed. No viable offspring has been obtained. However, other systems such as Sleeping Beauty or CRISPR/Cas technology are in place that may show better performance . Nevertheless, as the presence of non‐functional PERV relicts does not affect the quality of xenotransplants, pigs free of functional PERV‐C should be used as founder animals for breeding. Their offspring should be chosen as donor animals for xenotransplantation. The expected increase in xenotransplantation events when starting first in man trials will possibly lead to marketing authorized medicinal products. As such, xenotransplants could be placed on the market. Even if no patient was affected yet, it does not necessarily mean that PERV does not have the potential for being infectious in vivo either in susceptible and/or immunosuppressed patients. In addition, PERV transmission in different human cell lines was repeatedly demonstrated in vitro in the past, which shows that a putative potential risk may exist and should not be ignored. For this reason, pigs have to be selected carefully to exclude the slightest risk. At any rate, the generation of pigs without expression of functional PERV remains the major goal given that the absence of the retrovirus is prevention at its best. Update on PERV detection assays Diagnostic detection of PERV transmission via cocultivation A sensitive and established test for PERV transmission is the cocultivation of PERV producer cells and human target cells. In practice, virus‐producing cells were exposed to a certain, lethal irradiation dose so that producer cells died a few days post‐cocultivation. The irradiation dose depended on the source and had to be adjusted individually in a pre‐experimental setting . Putatively infected cells were exclusively cultivated until monitoring time had expired, usually after 4–8 weeks. By means of this system, discrimination between PERV releasing cells and PERV target cells was guaranteed to the greatest possible extent . Based on this strategy, activated porcine peripheral blood mononuclear cells (poPBMC) were cocultivated with human embryonic kidney (HEK) 293 cells . The results obtained were of great importance. The capacity of PERV‐C to be recombined with PERV‐A in vitro was demonstrated for the first time. Furthermore, the assay revealed a chance to analyze the infectious potential of functional PERV as well as the susceptibility of certain cell lines for PERV. The newly recombined PERV‐A/C infected human cell lines ex vivo at titers higher than those observed for parental PERV particles. In addition, outcomes of the same study revealed that PERV‐A/C expressed in producer 293/PERV‐NIH‐3° cells just as poPBMC fail to infect human PBMC (huPBMC) in cocultures . This indicated that huPBMC express a solid innate immunological barrier apparently counter‐regulating PERV during infection. The cocultivation of gamma‐irradiated virus‐producing cells with target human cells has become a common approach . Nevertheless, this methodology bears a great disadvantage. The cells are not strictly separated, and the only method to eliminate the PERV source is to irradiate the producer cells. This scenario significantly deviates from the real situation of pig‐to‐human xenotransplantation, and it may affect the characteristics of PERV as well. In the newly developed cocultivation strategies, the implementation of a two chamber system was a significant improvement . This system is based on target cells that are seeded, for example, in the bottom of 6‐well plates combined with upper hanging cell culture inserts containing the producer cells. The PERV producer cells are separated from pre‐seeded target cells by a porous membrane . The pore size of 0.4 μ m allows microcirculation of small particles and viruses through the membrane resulting in intercellular communication as well as receptor‐mediated virus infection. However, cell migration into the subsection with target cells is impeded and previously observed side effects such as microchimerism are avoided. This assay offers two possibilities, first to investigate PERV infectious potential and second to differentiate PERV‐susceptible from non‐susceptible cells. This in vitro scenario mimics the in vivo pig‐to‐human xenotransplantation event as closely as possible given that both cell types ( virus donor and virus target) were maintained viable during the entire cocultivation experiment . The intracellular communication via small molecules that is enabled by virtue of the cocultivation strategy opens new avenues to explore immunological or further virological aspects involved in PERV infection and counteraction in target cells. The feasibility of this approach was demonstrated successfully in different studies that were aimed to address PERV infectious potential. Cocultivation of 293 cells producing either the PERV‐A/C recombinant PERV/5° or PERV‐B with mouse 3T6 cells resulted in a non‐productive infection of mouse cells as no PERV provirus was detected in 3T6 cells by PCR specific for each PERV class . Another study described the non‐capacity of PERV expressed by mitogenically activated poPBMC purified from Göttingen minipigs to infect permissive human 293 cells via cocultivation. Except for positive control experiments, which involved the cocultivation of PERV/5°‐producing 293 cells with naive 293 cells, no provirus was detected in target 293 cells . The advantage of cocultivation without preceding irradiation is obvious. Both cell types are maintained viable during the complete experimental time, and irradiation of primary virus source was not required. Virus particles are able to diffuse through the membrane and infect susceptible target cells without any risk of microchimerism. Due to these options, the coculture technique could be introduced as a new standard. It may be used to select animals for cloning that have revealed no transmission of PERV. The testing and selection of parents being negative for transmission after coculture experiments could be the basis for the generation of transmission‐negative donor animals. Quantitative and differential gene expression profiling by microarray analysis Besides the other well established molecular screening methods microarray technology evolved as a powerful diagnostic tool. It is suitable for multiplex, selected detection, and characterization of microorganisms including bacteria, viruses, fungi, or parasites in patient samples and/or medicinal products intended for human application . The scope for microarray analyses is widespread reaching from peptide or protein arrays via RNA—to dsDNA—or ssDNA arrays as well as Exon‐ and miRNA microarrays that are available, for example, for custom gene expression and species‐specific genome analysis. They basically follow the same principle. Distinct probes are spotted as discrete features on a solid surface, commonly glass slides and hybridized, for example, with a fluorescent cyanine dye labeled sample of interest. This sample contains the so‐called target sequences, which should exclusively hybridize with its complementary probes. Detection occurs by measurement of the fluorescent intensity with an, for example, specific laser‐induced fluorescence scanner, counting all features that exceed the application‐dependent background limit according to internationally specified guidance values . The DNA microarray techniques available for gene expression profiling or analysis of genomic DNA among others range from printed DNA microarrays, in situ‐synthesized oligonucleotide microarrays, suspension bead arrays to high‐density bead arrays. The number of features ranges from less than a hundred (low‐density arrays) up to 1 million (high‐density arrays). Commercially available systems hereby provide a broad range of different preselected collections as well as custom designs. According to probe design and application, microarrays vary in their specificity and sensitivity for the expected target by assigning short or long probe sequences ranging, for example, from 20 nucleotides (20‐mer) up to 150 nucleotides (150‐mer) that are directed against a unique sequence of the corresponding target gene . In this case, DNA quality is the crucial factor as any mismatch has a dramatic impact on the performance of oligonucleotides while influencing the stability of duplex formation and its great dynamic range. Another important factor is the level of signal‐to‐noise ratio that is most relevant to achieve significant results. According to Hughes et al., the absolute detection limit of 60‐mer oligonucleotide consisting ink‐jet arrays is close to 0.1 copies/cell equivalent, or 1 : 1 000 000, based on 100 000 transcripts/cell . As microarray technology has already been successfully used for retroviral/viral screening including human endogenous retroviruses (HERV) or exogenous retroviruses such as HIV or HTLV , avian influenza virus , coxsackie, and other enteroviruses as well as applications in clinical diagnosis , it is obvious to manifest this method as a PERV detection assay to support routine analysis of quality and safety of porcine‐derived products. In a recent approach, highly specific porcine diagnostic gene probes were spotted in a customized design ( MyArray ; OakLabs GmbH, Hennigsdorf, Germany) as 8x60K arrays . Probe data were derived from the annotated complete draft pig genome sequence, published by the Swine Genome Sequencing Consortium in November 2012 . These data comprise relevant porcine inflammatory and host restriction factors amended by conserved regions of PERV‐A/‐B/‐C env and prt/pol and selected human transgenes. The data may reveal comprehensive information on the retroviral status as well as on tissues viability and quality that far exceeds the properties of multiplex PCR or RT‐PCR that are solely used for affirmative analysis. In summary, microarray technology in combination with quantitative RT‐PCR, for example, for selected genes allows cost‐efficient testing of samples within the given and often restricted shelf life of the product. It does reveal the specific PERV status on the one hand and provides broad information on differential gene expression profiles on the other hand. This fast method is suitable for parallel testing of different samples derived from one or several putative donor animals. Furthermore, it may reveal the effect of gene transfer/knockout on the expression profile of selected target cell lines that are potentially intended as ATMP. RNA‐Seq In addition to microarray analyses, genome technologies provide another meaningful tool for pathogen detection and gene expression analysis. Deep sequencing technologies such as RNA‐Seq are intended to enable precise measurement of levels of transcripts and their isoforms not restricted to a predetermined selection of probes for particular targets. By maintaining a sufficient reading depth and read length, RNA‐Seq is a well‐suited detection method for qualitative expression profiling, generally comparable with microarray analysis, particularly for organisms encompassing unknown genomic sequence targets . As such, RNA‐Seq constitutes an indispensable method for foreign pathogen detection, PERV expression profiling, and subsequent transcriptome analysis. It is sufficient for the selection of suitable animals intended for xenotransplantation or screening of qualified animals that are intended for further pathogen‐free breeding. As it is not limited to a certain number of gene targets, it offers the chance to identify novel candidate genes and gene polymorphisms as shown in recent studies on boar testis and liver tissues as well as in other reference organisms . The issues of microarrays and deep sequencing are new for pigs in general. They are considered as general assays capable of covering PERV‐specific issues such as expression levels as well as the effect(s) on cells looking into the differential gene expression profiles. In addition to the microbial safety aspect, both assays provide a broad insight into the expression status of cells, for example, for comparative analysis of native and genetically modified cells and cell lines. Regulatory requirements In addition to the scientific approaches, biological medicinal products intended for placing on the market require marketing authorizations, based on the regulatory requirements of the appropriate national agencies and competent authorities in conformity with their legal frameworks. In Europe, xenogeneic products are subject to the regulations of ATMPs, which are established in Regulation (EC) No 1394/2007 . The European Medicines Agency (EMA) provides the necessary information for applicants on classification and certification of the quality and non‐clinical data including support to companies and guidance on the valid regulatory framework. Furthermore, for xenogeneic cell‐based medicinal products that are dedicated to the field of cell therapy and tissue engineering, specific regulatory information is provided in the CHMP Guideline on xenogeneic cell‐based medicinal products (EMEA/CHMP/CPWP/83508/2009). The guideline on xenogeneic cell‐based medicinal products addresses the minimum requirements regarding quality and manufacturing aspects including testing. It has a focus on source animals, their procurement, and processing in GMP‐certified manufacturing facilities. In particular, the surveillance of known and unknown infectious agents in source and founder animals that are kept under SPF conditions, with adequate and validated diagnostic assays is the basis for appropriate quality assurance. Advice on microbial testing methods and their validation is among other sources given in the European Pharmacopoeia, Ph. Eur. 5.1; 5.1.6; 2.6.1, and 2.6.27. The methods should be well defined and should follow appropriate laboratory assurance standards. For pigs as source animals, besides zoonotic, human pathogenic microbial agents, special consideration is given to the screening of porcine endogenous retroviruses (PERV). It is advised to apply methods such as hybridization, antibody testing, and/or PCR as well as classical methods such as pathology and histopathology. The relevant CHMP guidelines for clinical trials, including the guideline on human cell‐based medicinal products (EMEA/CHMP/410896/2006) , should be taken into account as recommended in EMEA/CHMP/CPWP/83508/2009 . Nevertheless, the evaluation of a clinical trial including its safety and risk evaluation especially in the field of ATMPs requires a product‐specific assessment process, which depends on the current legal framework as well as on the growing knowledge on advanced therapy medicinal products. Further information is provided, for example, by European Parliament, WHO and Council of Europe recommendations . In the USA, the use of xenotransplantation products in humans is regulated by the Food and Drug Administration (FDA) as the competent authority. A regulatory framework is provided by the Guidance for Industry documents published in 2002 and 2003 . Outlook The presented update on assays for PERV detection and gene expression analysis displays a wide diversity of testing methods that support the generation of pigs as donors of tissues and cells to fulfill the regulatory prerequisites on safety and quality according to the international regulatory requirements for xenotransplantation clinical trials . The choice of methods strongly depends on the target materials and needs adaptation to each approach. The selection of PERV‐C free, PERV‐A/‐B low‐producer animals in addition to the full assessment of the microbial background including potential zoonotic microorganisms and environmental microorganisms incorporated during processing is indispensable . Methods on cocultivation and gene expression profiling offer new approaches to generate data that help to evaluate the risk/benefit balance of the individual product to provide safe xenotransplants in the future . Acknowledgments We thank Nicole Fischer and Constanze Taylor for critical reading of the manuscript, and our national and international colleagues and cooperation partners for the scientific results presented here and the encouragement to write this review. Funding This work was supported by grant SFB 127 from the Deutsche Forschungsgemeinschaft, DFG, Bonn, Germany. Authors' contributions The manuscript was equally drafted by Antonia W. Godehardt, Michael Rodrigues Costa and Ralf R. Tönjes.
Xenotransplantation – Wiley
Published: Mar 1, 2015
You can share this free article with as many people as you like with the url below! We hope you enjoy this feature!
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.